Drug Profile


Alternative Names: Feraheme; Ferrosoferric oxide; Rienso

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AMAG Pharmaceuticals
  • Class Antianaemics; Contrast media; Diagnostic agents; Ferric compounds; Ferrous compounds; Heavy metals; Minerals
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Peripheral arterial disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase II Peripheral arterial disorders

Most Recent Events

  • 14 Feb 2017 AMAG Pharmaceuticals completed enrolment in a phase III trial for Iron deficiency anaemia in USA (IV) (NCT02694978)
  • 12 Oct 2016 AMAG Pharmaceuticals announces intention to submit sNDA to the US FDA in mid-2017
  • 19 Sep 2016 AMAG Pharmaceuticals terminates two phase-III clinical trials in Iron deficiency anaemia (in children) in USA (IV) (NCT01155375; NCT01155388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top